secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001213900-26-046671
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds gets NYSE American delisting notice for late 10-K; trading halt continues
--------------------------------------------------------------------------------

- Received NYSE American notice on April 17, 2026 for failure to file 2025 10-K on time.
- Has initial 6-month cure period until October 15, 2026; expects to file 10-K by April 30.
- Common stock trades with '.LF' designation; trading halt from April 2 remains in effect.
- If not cured, NYSE may grant up to 6 additional months or commence delisting procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026046671/0001213900-26-046671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026046671/ea028720301-8k_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-046671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer